search
Back to results

Long-term Study of KAD-1229 in Type 2 Diabetes Patients

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
KAD-1229
Sponsored by
Kissei Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Type 2 diabetes, HbA1c, Long-term study

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy
  • Age in the 20 years or over inclusive
  • HbA1c in the range of ≥ 6.5 to < 9%

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Patients with serious diabetic complications and other serious complications

Sites / Locations

  • Japan

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

KAD-1229

Arm Description

Outcomes

Primary Outcome Measures

Incidences of Adverse Events

Secondary Outcome Measures

Change From Baseline in HbA1c at 52 Weeks

Full Information

First Posted
April 6, 2011
Last Updated
November 27, 2014
Sponsor
Kissei Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT01333592
Brief Title
Long-term Study of KAD-1229 in Type 2 Diabetes Patients
Official Title
A Multicenter, Open Label, Long-term Study of KAD-1229 in Type 2 Diabetes Patients Who Show Inadequate Glycemic Control With Diet, and Biguanide or DPP-4 Inhibitor Monotherapy
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
November 2012 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Kissei Pharmaceutical Co., Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the long-term safety and efficacy of KAD-1229 as combination therapy with biguanide or DPP-4 inhibitor in type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Type 2 diabetes, HbA1c, Long-term study

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
136 (Actual)

8. Arms, Groups, and Interventions

Arm Title
KAD-1229
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
KAD-1229
Primary Outcome Measure Information:
Title
Incidences of Adverse Events
Time Frame
52 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in HbA1c at 52 Weeks
Time Frame
at week 0 and week 52

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy Age in the 20 years or over inclusive HbA1c in the range of ≥ 6.5 to < 9% Exclusion Criteria: Type 1 diabetes mellitus Patients with serious diabetic complications and other serious complications
Facility Information:
Facility Name
Japan
City
Kanto region, Chugoku region, Kyushu region
Country
Japan

12. IPD Sharing Statement

Learn more about this trial

Long-term Study of KAD-1229 in Type 2 Diabetes Patients

We'll reach out to this number within 24 hrs